objectives The poor detection rate of multidrug-resistant tuberculosis (MDR-TB) highlights the urgent need to explore new case finding model to improve the detection of MDR-TB in China. The aim of this study was to evaluate the feasibility of a new model that combines molecular diagnostics and sputum transportation for early detection of patients with MDR-TB in Zhejiang.
Introduction
Tuberculosis (TB) remains a global public health concern [1] . In 2015, WHO estimated that there were 10.4 million new cases and 1.4 million deaths from tuberculosis worldwide [1] . After India and Indonesia, China has the third-highest TB burden in the world, with an estimated 0.8 million new TB cases annually [1] . Due to the effective national TB control effort, China has more than halved its TB prevalence in the past 20 years [2] , but the epidemic of multidrug-resistant TB (MDR-TB), defined as resistance to both rifampin (RIF) and isoniazid (INH), threatens the progress of TB control and prevention in China [3, 4] . According to a national drug-resistant TB survey in China, 5.7% and 25.6% of new and previously treated TB cases were infected with MDR-TB, respectively [3] . Out of the estimated 57 000 MDR-TB cases in 2015, only 10 000 were reported to WHO [1] . The main barrier to diagnosis of MDR-TB is the lack of access to universal drug susceptibility testing in resource-limited settings with a high prevalence of drug-resistant TB [5] . There is no doubt that the missing MDR-TB patients would lead to the transmission of MDR-TB in the community [6] . Hence, the poor detection rate of MDR-TB highlights the urgent need to explore new case finding model to improve the detection of MDR-TB in China.
Conventional phenotypic drug susceptibility testing (DST) is the gold standard to diagnosis of MDR-TB. Unfortunately, due to the slow growth rate of Mycobacterium tuberculosis (MTB), it requires about 2-3 months to diagnose the illness [7, 8] . The lengthy timeline delays the initial of effective drug therapy for MDR-TB patients [9] . The recent development of rapid diagnostic technology speeds detection of MDR-TB from 2 months to 1 day [10] . WHO has endorsed several commercial technologies for diagnosing MDR-TB, including Xpert MTB/ RIFâ assay and line probe assay (LPA) [11, 12] . They are performed directly on sputum, with a turnaround time of a few hours, which preferably meets clinical requirements. In view of the intrinsic advantages of these molecular diagnostics, they may provide the potential solution for the dilemma regarding low detection rate of MDR-TB in China.
Zhejiang province is located in eastern China, covering an area of 101,800 square kilometres and with a population of 55.4 million in 2015 [13] . As a pilot province of the Global Fund, Zhejiang launched the MDR-TB project focusing the patients with drug-resistant TB at high-risk from 2008 to 2013. Although this case finding strategy is more cost-effective, more than half of patients with MDR-TB come from those without any anti-TB treatment history in China [3] . This biased screening strategy, therefore, halves the detection of MDR-TB cases. Under the support from the Global Fund, one-third of county-level and prefecture-level laboratories in Zhejiang have been equipped with GeneXpert and LPA in 2014, respectively [14] . We speculated that the integration of these new diagnostics would enhance the case finding of MDR-TB compared with the conventional procedure. Therefore, this study aimed to evaluate the feasibility of a new model that combined molecular diagnostics and sputum transportation for early detection of patients with MDR-TB in Zhejiang.
Methods

Ethics approval
This study was approved by the Ethics Committee of Zhejiang Center for Disease Control and Prevention. All the patients enrolled in this study gave informed consent.
Specimen collection
From May 2014 to January 2015, TB suspects who had cough, expectoration or hemoptysis for more than 2 weeks were continuously enrolled at six county-level designated TB hospitals in Quzhou, Zhejiang. Each patient was asked to give three sputum samples for laboratory examination, comprising one spot, one morning and one night sputum. All sputum specimens were submitted to laboratory for smear microscopy, solid culture and GeneXpert.
Laboratory examination
Direct smears of each sputum specimen were examined using Ziehl-Neelsen (ZN) staining for acid fast bacilli (AFB) [15] . One specimen, with highest smear-positive grade for smear-positive specimen or with good quality for smear-negative specimen, was selected from each patient for solid culture and GeneXpert. For solid culture, 1 ml of sputum was digested with N-acetylcysteinesodium hydroxide (4%) for 15 min, and then inoculated onto modified Lӧwenstein-Jensen (L-J) medium according to previous description. In addition, 1 ml of residual specimen was detected by GeneXpert following the instruction from the manufacturer [16] . The specimens from RIFresistant cases detected by GeneXpert were transported from county-level laboratory to prefecture-level laboratory for LPA analysis following the manufacturer's instructions.
In addition, all positive MTB isolates were transported to prefecture-level laboratories for conventional drug susceptibility testing (DST). Indirect drug susceptibility of the culture-positive isolates was detected by the proportion method according to the recommendation of WHO [4] . The concentrations of drugs in media were as following: INH 0.2 lg/ml and RIF 40 lg/ml. The strain was declared resistant to the corresponding drug when the growth rate was higher than 1% compared to the control. Strains resistant to INH and RIF determined by either phenotypical DST or LPA were defined as MDR-TB.
Data analysis
Statistical analysis of the data used Microsoft excel spreadsheets and SPSS v.15.0 (SPSS Inc., Chicago, IL, USA). Student's t-test was used for statistical comparisons. A P value of less than 0.05 was considered significant. The performance of GeneXpert was evaluated using conventional L-J culture as gold standard, including sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV).
Results
Performance of GeneXpert for detecting patients with TB
A total of 3151 sputum specimens were collected from TB suspects (Figure 1 ). Of these 2704 were culture-negative and nine were contaminated during culture. 46 samples yielded invalid GeneXpert results, including one culturepositive sample. Therefore, 3096 of 3151 samples were used for further analysis. Overall, when using the conventional L-J culture as gold standard, the sensitivity of GeneXpert for detecting culture-positive cases was 92.7% [(405/437, 95% confidence interval (95%CI): 90.3-95.1)], while GeneXpert could also identify 2428 of 2659 culture-negative cases, demonstrating a specificity of 91.3% (95% CI: 88.9-94.5; Table 1 ).
Detection of RIF-resistant and MDR-TB cases
All positive cultures were transported to prefecture-level laboratories for DST examination, and 16 (3.7%) of 437 cases were diagnosed as RIF-resistant: eight MDR-TB and eight RIF mono-resistant TB (Table 2) . For the 21 RIF-resistant cases by GeneXpert, the sputum samples were further analysed by LPA. As shown in Figure 1 , there were eight and three MDR-TB cases detected from patients with smear-positive and smear-negative, respectively. We further compared the performance of GeneXpert to detect RIF resistance with conventional L-J DST. Of 16 RIF-resistant cases detected by DST, GeneXpert could correctly identify 15 cases, yielding a sensitivity of 93.8% (15/16, 95% CI: 91.4-96.2). The specificity of GeneXpert for detecting RIF susceptibility was 100.0% (383/383, 95% CI: 100.0-100.0). Invalid (46) Negative (2704) Contaminated (9) Positive (438) Figure 1 Enrolment of patients in this study.
Interval of MDR-TB detection
The intervals of MDR-TB detection by different models are summarised in Figure 2 . The average interval to diagnosis of the conventional DST model was 56.5 days, ranging from 43 to 71 days, which was significantly longer than that of GeneXpert plus LPA model (22.2 days, P < 0.01). Among the GeneXpert plus LPA model, a great diversity of interval of MDR-TB was observed between smear-negative and smear-positive specimen group, and the average interval to diagnosis for smear-positive specimens took significantly less time than that for smear-negative specimens (10.1 days vs. 32.3 days, P < 0.01).
Discussion
We investigated the feasibility of a new model with GeneXpert for early detection of MDR-TB patients in China and found that the combination of improved molecular TB tests and sputum transportation could significantly shorten the time required for detection of MDR-TB, from 56.5 days by conventional bacteriologic procedure to 22.2 days by the new model. Numerous reports have demonstrated that delay in the diagnosis of TB will worsen the prognosis of anti-TB treatment and enhance its transmission in the community [17, 18] . In China, because of the barrier to access to drug susceptibility testing, only 11% of MDR-TB cases were diagnosed in 2014 [19] , and a majority of patients with MDR-TB received a first-line anti-TB regimen in county-level TB hospitals. After several months of ineffective therapy, they may be transferred to prefecture-level hospital for further DST examination. The poor clinical outcome associated with diagnosis delay could be expected for these cases. Hence, the application of this new model would enhance the early diagnosis of MDR-TB cases and further bring benefit for preventing the epidemic of MDR-TB in this setting with high prevalence of MDR-TB.
Mycobacterial culture is considered the gold standard for the diagnosis of patients with TB [20] , which provides the highest sensitivity to detect the mycobacteria from clinical specimens. However, our data revealed that the positive rate of GeneXpert (20.3%, 641/3151) for detecting TB was higher than that of solid culture (13.9%, 438/3151). Although the exact reason remains unknown, we hypothesise that the low sensitivity of solid culture is contributing to the poor quality of sputum samples [21, 22] . The optimal laboratory diagnosis of mycobacterial infection relies on the collection of appropriate and adequate specimens [22] . In this study, more than 30% of sputum specimens were saliva sputum (data not shown), which may be the major reason for the low positive rate. Interestingly, GeneXpert outperforms solid culture to detect mycobacteria from these specimens with poor quality. Compared with the automated GeneXpert, mycobacterial culture requires multiple carefully timed processes. To increase efficiency, the decontamination step is always performed on batches of specimens rather than on individual specimens. Hence, the time treated with alkaline condition may vary depending on the number of specimens in each batch, thereby affecting the diagnostic value of mycobacterial culture. In view of the high prevalence of TB, GeneXpert provides an alternative for yielding strong evidence for the diagnosis of patients with smear-negative in the county-level laboratories with limited settings. In addition to patients with bacteria positive pulmonary TB, our data demonstrated that GeneXpert was analytically highly sensitive and specific for identifying patients with RIF-resistant TB. However, we acknowledge that the small sample size of RIF-resistant MTB isolates enrolled in this study may encumber the performance analysis of GeneXpert in the detection of RIF resistance and limit the generalisability of the findings.
Previous molecular epidemiological studies have demonstrated that 90% of RIF-resistant TB strains exhibit resistance to INH, RIF resistance therefore serves as an indicator for MDR-TB [23] . In contrast, a recent report from China found that more than 30% of RIFresistant strains were susceptible to INH [8] . Similar to the latter, our results showed that half of RIF-resistant strains were not MDR-TB in Zhejiang. Considering that INH is the cornerstone of TB therapy, the loss of INH in the treatment of patients with RIF mono-resistant TB is unreasonable. Hence, further analysis of INH susceptibility after the detection of RIF resistance by GeneXpert is urgently needed to make a final diagnosis of MDR-TB. Another interesting finding of this study is the remarkably low prevalence of RIF resistance in this region compared with the average national level of 11.7%. The low prevalent rate of RIF resistance in the regions will lead to a high false positive value. According to a recent document WHO, RIF-resistant cases detected by GeneXpert should be confirmed by conventional susceptibility testing or another molecular diagnostic [24] . Taken together, these data strongly support the further application of LPA in this novel model to improve the diagnostic accuracy of GeneXpert in the clinical practice in Zhejiang.
Despite the obvious advantages of this model, several concerns should be addressed. First, the cost of GeneXpert testing is far from negligible [25, 26] . Further costeffectiveness analysis of the model is required to carefully propose its use for policy marker. Second, the frequency of sputum transportation is another issue in the implementation phase. A previous study by Pang and colleagues found that the invalid rate of molecular diagnostic was significantly increased if the storage of sputum specimens exceeded 7 days [27] . Hence, we recommend that samples should be transported weekly, taking the cost of transportation into consideration.
Conclusions
In conclusion, our data demonstrate that the combination of improved molecular TB tests and sputum transportation could significantly shorten the time required for detection of MDR-TB, which will bring benefits for preventing an epidemic of MDR-TB in this high-prevalence setting. Further study regarding the cost-effectiveness analysis of the model is urgently needed to carefully propose its use for policy makers.
